Safety and Efficacy of GLP-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis

Researchers conducted this systematic review and meta-analysis to determine the weight, BMI, cardiometabolic and gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity.

Data were obtained from 574 children and adolescents, 302 of which received a GLP-1RA. GLP-1 receptor agonists use caused a modest decline in body weight, BMI, and BMI z-score. In children with proven insulin resistance, glycemic control was improved. This meta-analysis found that GLP-1 receptor agonists are safe and effective in clinical settings for reducing weight, BMI, HbA1c, and systolic blood pressure in children and adolescents with obesity, though with increased rates of nausea.
Masters of Pediatrics™ (MoP) is dedicated to the advancement of healthcare technologies and education serving as the academic home for child health professionals. Masters of Pediatrics offers continuing medical education, activities, and training through its advanced education entity Metabolic Medical Institute (MMI).
A division of Tarsus Medical owned by Tarsus Group

+1 (888) 555-1212

Copyright © 2022, A4M. All trademarks, registered or unregistered, are the property of their respective owners.